Showing 2181-2190 of 2881 results for "".
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Homehttps://practicaldermatology.com/news/fda-clears-philips-bluecontrol-wearable-light-therapy-device-to-treat-mild-psoriasis-at-home/2458124/The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical device designed for home use. Clinical studies have demonstrated that the UV-free blue LED
- High Doses of Sunshine Vitamin May Improve Sunburnhttps://practicaldermatology.com/news/high-doses-of-sunshine-vitamin-may-improve-sunburn/2458128/High doses of vitamin D taken one hour after sunburn may significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center.
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients
- Topical Cannabinoids May Soothe Itchy Skinhttps://practicaldermatology.com/news/topical-cannabinoids-may-soothe-itchy-skin/2458218/Cannabinoids contain anti-inflammatory properties that may make them useful in the treatment of a wide-range of skin diseases including eczema, psoriasis, atopic and contact dermatitis, according to researchers at the University of Colorado Anschutz Medical Campus. The new study app
- Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatologyhttps://practicaldermatology.com/news/novan-forms-new-advisory-council-focused-on-nitric-oxide-technologies-in-dermatology/2458228/Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- New Combo Therapy Beats Out Gold Standard Treatment For AKshttps://practicaldermatology.com/news/new-combo-therapy-beats-out-gold-standard-treatment-for-aks/2458360/Combining a cream formulation of 5-fluorouracil with a synthetic form of vitamin D called calcipotriol may trigger a robust immune response against actinic keratosis, according to research out of rom Washington University School of Medicine in St. Louis and Harvard Medical School in Boston.
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The r
- Sweden Greenlights Allergan's Double Chin-Melting BELKYRA®https://practicaldermatology.com/news/sweden-greenlights-allergans-double-chin-melting-belkyra/2458404/The Swedish Medical Products Agency has greenlighted Allergan’s BELKYRA® (deoxycholic acid) for submental fat reduction. BELKYRA® is already licensed in Canada, Australia, Iceland, Hungary, Austria, Lithuania, Estonia, Latvia, Romania, Bulgaria and Norway, as well